Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 256

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 8
Chunk 256
---

that restrict or affect our import or export of capital, including the availability of cash and cash equivalents for use by us and our
wholly owned subsidiaries, or the remittance of dividends, interest or other payments to non-resident holders of our securities, except
for shareholders who are subjects of countries that are, or have been, in a state of war with Israel or otherwise as set forth under “ Item
10E. Additional Information - Taxation.”

E. Taxation

The following description is not intended to
constitute a complete analysis of all tax consequences relating to the ownership or disposition of our ordinary shares or ADSs, both referred
to in this Item 10E as the ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular
situation, as well as any tax consequences that may arise under the laws of any state, local, non-U. S., including Israeli, or other taxing
jurisdiction.

Israeli Tax Considerations

The following is a summary of the material Israeli tax laws applicable
to us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our shares.
This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her
personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind
of investor include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion.
To the extent that this discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation,
we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. The discussion
below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations
of Israeli law, which change could affect the tax consequences described below.

General Corporate Tax Structure in Israel

Israeli companies are generally subject to corporate tax on their
taxable income. The regular corporate tax rate in Israel is 23% for the year 2018 and thereafter. Capital gains derived by an Israeli
company are now generally subject to tax at the same rate as the corporate tax rate.

As of December 31, 2024, the tax loss carryforwards of BioLineRx
were approximately $343 million with no expiration date.

Taxation of Israeli Individual
Shareholders on Receipt of Dividends. Israeli residents who are individuals are